We are delighted to confirm the following international and national
invited faculty for the 2022 SABR Symposium.
Prof. Filippo Alongi MD is Head of Advanced Radiation Oncology Department at IRCCS Sacro Cuore Don Calabria Cancer Care Center of Negrar in Verona, Italy and Associate Professor at University of Brescia, Italy.
Prof Alongi has had various positions within the Italian Association of Radiotherapy and Clinical Oncology (AIRO), including the role of national coordinator of the under 40 group and national secretary of the prostate group. He was a member of both the Executive Board and the National Scientific Committee, and was the National Coordinator of the uro-oncological group. He is currently the Coordinator of oligometastases AIRO group.
Prof. Alongi is the author of several book chapters, and more than 320 scientific articles on radiotherapy and oncology. He has been lecturer at more than 250 meetings and university courses, in Italy, Europe and other countries, including US. He presented more than 200 scientific communications as a speaker at national and international congresses / symposia. He is a member of the "Editorial Board" for several journals in oncology and radiotherapy (including Radiation Oncology, Technology in Cancer Research and Treatment, Tumori Journal) and is a reviewer for the EORTC, the European Organization of Research and Treatment of Cancer.
Dr. Daniel Gomez attended college at the University of Virginia and went to medical school at the University of California, San Francisco. He completed a residency in radiation oncology at Memorial Sloan Kettering Cancer Center. He then joined as a faculty member at MD Anderson Cancer Center, where he ultimately served as Clinical Medical Director of Radiation Oncology and led the Thoracic Radiation Oncology team. In 2019, Dr. Gomez joined the faculty of Memorial Sloan Kettering Cancer Center and currently serves as both the Director of Thoracic Radiation Oncology and the Vice Chair of Clinical Operations for the department. He continues to spearhead operational efforts for the department and publish clinical and translational studies in lung cancer.
Professor Gerry Hanna is the Clinical Director for Oncology at the Northern Ireland Cancer Centre, Belfast City Hospital and holds honorary appointments at Queen’s University Belfast and the University of Melbourne and is the past Director of Radiation Oncology at the Peter MacCallum Cancer Centre in Melbourne.
Professor Hanna’s research interests are the use of PET/CT in radiotherapy planning for lung cancer, mechanisms of radiotherapy resistance, technical radiotherapy, stereotactic ablative radiotherapy and systemic therapy and immunotherapy combinations with radiotherapy. He is chief investigator of the International Atomic Energy Agency’s “PERTAIN” study and previous co-chief Investigator of the CONCORDE study, a UK study of novel agents in combination with radiotherapy in the treatment of lung cancer. He is a TMG member for the UK’s HALT, SARON and CONFIRM studies. Away from work he enjoys cycling, good music and pretending to play the piano.
Dr. Jennifer Dolan is the director of MR-guided radiation therapy physics at the Henry Ford Cancer Institute in Detroit, Michigan, where she also serves on the radiosurgery physics team. Dr. Dolan received her PhD in Nuclear Engineering and Radiological Sciences from the University of Michigan in 2013. Upon completion of her studies, Dr. Dolan worked in the nuclear security and nuclear well logging fields. She returned to the University of Michigan in 2016 to obtain her certificate in medical physics and completed her residency at Henry Ford Health in 2019. Her research interests focus on MR guided adaptive radiation therapy and innovations in novel MR guided applications to radiation therapy.
Dr Alison Tree is a clinical researcher investigating the benefits of profoundly hypofractionated radiotherapy in urological cancers. She is involved in several national and international trials of innovative radiotherapy strategies, and has a particular interest in prostate cancer.
Dr Alison Tree was appointed as a consultant clinical oncologist at The Royal Marsden NHS Foundation Trust in 2014, specialising in radiotherapy and chemotherapy treatment for urological malignancies. Her MD thesis was on stereotactic body radiotherapy (SBRT) techniques for prostate and oligometastatic cancer.
Her current research interests focus on technical radiotherapy improvements in prostate cancer, aiming to make radiotherapy more effective and reduce side effects. Dr Tree leads the Prostate Group in the International MR Linac consortium. She is currently leading trials in MR-guided prostate radiotherapy (the PRISM trial), boosting dominant intra-prostatic lesions (the DELINEATE trial) and ablating oligoprogressing metastases in advanced prostate cancer (the TRAP trial). She will soon be starting the HERMES trial which is testing whether prostate cancer can be cured in just 2 fractions.